StockData
TWSTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30

Twist Bioscience Corp

Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$139.77+7.02 (+5.29%)

Close on Oct 19, 2026

Market cap
$8.72B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 13, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q3 FY2026
Ended Jun 30, 2026
Aug 3, 2026Before market open$118.40M––
Q2 FY2026
Ended Mar 31, 2026
May 4, 2026Before market open$110.70M––
Q1 FY2026
Ended Dec 31, 2025
Feb 2, 2026Before market open$103.70M$-0.50–
Q4 FY2025
Ended Sep 30, 2025
Nov 14, 2025Before market open$99.00M$-0.45–
Q3 FY2025
Ended Jun 30, 2025
Aug 4, 2025Before market open$96.10M$0.33–
Q2 FY2025
Ended Mar 31, 2025
May 5, 2025Before market open$92.80M$-0.66–
Q1 FY2025
Ended Dec 31, 2024
Feb 3, 2025Before market open$88.70M$-0.53–
Q4 FY2024
Ended Sep 30, 2024
Nov 18, 2024Before market open$84.70M––
Q3 FY2024
Ended Jun 30, 2024
Aug 2, 2024Before market open$81.50M$-1.47–
Q2 FY2024
Ended Mar 31, 2024
May 2, 2024After market close$75.30M$-0.79–
Q1 FY2024
Ended Dec 31, 2023
Feb 2, 2024Before market open–––

Company guidance

Outlook given with results on Aug 3, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
Total revenuefull fiscal year 2026$456.00M to $457.00MRaised
growthfull fiscal year 202621% growthRaised
growthfourth quarter25% growthNew
Total revenuefourth quarter$123.00M to $124.00MNew

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Twist Bioscience filed with the SEC